345 related articles for article (PubMed ID: 23482733)
21. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ
Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504
[TBL] [Abstract][Full Text] [Related]
22. Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge.
Fung EC; Crook MA
Cardiovasc Ther; 2012 Oct; 30(5):e212-8. PubMed ID: 21884002
[TBL] [Abstract][Full Text] [Related]
23. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
Silva M; Matthews ML; Jarvis C; Nolan NM; Belliveau P; Malloy M; Gandhi P
Clin Ther; 2007 Feb; 29(2):253-60. PubMed ID: 17472818
[TBL] [Abstract][Full Text] [Related]
24. Pitavastatin: a new HMG-CoA reductase inhibitor.
Wensel TM; Waldrop BA; Wensel B
Ann Pharmacother; 2010 Mar; 44(3):507-14. PubMed ID: 20179258
[TBL] [Abstract][Full Text] [Related]
25. Monday, Wednesday, and Friday dosing of rosuvastatin in patients previously intolerant to statin therapy.
Mackie BD; Satija S; Nell C; Miller J; Sperling LS
Am J Cardiol; 2007 Jan; 99(2):291. PubMed ID: 17223437
[TBL] [Abstract][Full Text] [Related]
26. Statin myopathy: significant problem with minimal awareness by clinicians and no emphasis by clinical investigators.
Whayne TF
Angiology; 2011 Jul; 62(5):415-21. PubMed ID: 21421631
[TBL] [Abstract][Full Text] [Related]
27. Management of statin-intolerant patient.
Arca M; Pigna G; Favoccia C
Panminerva Med; 2012 Jun; 54(2):105-18. PubMed ID: 22525565
[TBL] [Abstract][Full Text] [Related]
28. The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients.
Degreef LE; Opdam FL; Teepe-Twiss IM; Jukema JW; Guchelaar HJ; Tamsma JT
Eur J Intern Med; 2010 Aug; 21(4):293-6. PubMed ID: 20603038
[TBL] [Abstract][Full Text] [Related]
29. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
[TBL] [Abstract][Full Text] [Related]
30. Rechallenging Statin Therapy in Veterans With Statin-Induced Myopathy Post Vitamin D Replenishment.
Kang JH; Nguyen QN; Mutka J; Le QA
J Pharm Pract; 2017 Oct; 30(5):521-527. PubMed ID: 27798247
[TBL] [Abstract][Full Text] [Related]
31. Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database.
Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Davidson MH
Clin Ther; 2007 Nov; 29(11):2385-94. PubMed ID: 18158079
[TBL] [Abstract][Full Text] [Related]
32. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
[TBL] [Abstract][Full Text] [Related]
33. Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies.
Mohassel P; Mammen AL
Muscle Nerve; 2013 Oct; 48(4):477-83. PubMed ID: 23519993
[TBL] [Abstract][Full Text] [Related]
34. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance.
Halbert SC; French B; Gordon RY; Farrar JT; Schmitz K; Morris PB; Thompson PD; Rader DJ; Becker DJ
Am J Cardiol; 2010 Jan; 105(2):198-204. PubMed ID: 20102918
[TBL] [Abstract][Full Text] [Related]
35. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
McKenney JM
Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
[TBL] [Abstract][Full Text] [Related]
36. Pitavastatin calcium: clinical review of a new antihyperlipidemic medication.
Yee LL; Wright EA
Clin Ther; 2011 Aug; 33(8):1023-42. PubMed ID: 21816477
[TBL] [Abstract][Full Text] [Related]
37. Statin safety: lessons from new drug applications for marketed statins.
Jacobson TA
Am J Cardiol; 2006 Apr; 97(8A):44C-51C. PubMed ID: 16581328
[TBL] [Abstract][Full Text] [Related]
38. Statin-related adverse events: a meta-analysis.
Silva MA; Swanson AC; Gandhi PJ; Tataronis GR
Clin Ther; 2006 Jan; 28(1):26-35. PubMed ID: 16490577
[TBL] [Abstract][Full Text] [Related]
39. Drug-drug interactions that interfere with statin metabolism.
Hirota T; Ieiri I
Expert Opin Drug Metab Toxicol; 2015; 11(9):1435-47. PubMed ID: 26058399
[TBL] [Abstract][Full Text] [Related]
40. Rosuvastatin: characterization of induced myopathy in the rat.
Westwood FR; Scott RC; Marsden AM; Bigley A; Randall K
Toxicol Pathol; 2008 Feb; 36(2):345-52. PubMed ID: 18362199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]